Contact information
Research groups
Lisa Stockdale
MPH, PhD
Senior Immunologist
Pre-erythrocytic Malaria Clinical Trials
Senior Immunologist
Pre-erythrocytic Malaria Clinical Trials
As the Senior immunologist in the pre-erythrocytic malaria vaccine group, I coordinate the clinical immunology of all R21/Matrix-M vaccine trials. These include trials studying vaccine immunogenicity in populations with co-morbidities, different age groups, and using alternative dosing regimens.
Having spent 5 years in Industry working in small molecule drug development, I completed a Master of International Public Health at York University, and a PhD in Tuberculosis Vaccine Immunology at London School of Hygiene and Tropical Medicine, before joining the Oxford Vaccine Group as a post-doc where I conducted research on Typhoid conjugate vaccine immunology and Covid-19 vaccine development and immunology.
I joined the Pre-erythrocytic Malaria group at the Jenner Institute in 2021. My research interests include correlates of vaccine-induced protection, investigation of mediators of antibody function, immunological interactions between different pathogens and sero-epidemiology.
I am an Early Career Researcher representative for the Medical Sciences Division and the Nuffield Department of Medicine and a lead of the Jenner Research Staff Network.
Recent publications
-
A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against Mycobacterium avium complex subspecies in patients with active Crohn's disease.
Sanderson J. et al, (2025), EBioMedicine, 113
-
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01<sub>E</sub>.
Ali MS. et al, (2025), NPJ vaccines, 10
-
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
-
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Venkatraman N. et al, (2025), The Lancet. Microbe
-
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.
Stockdale LK. et al, (2025), NPJ vaccines, 10